Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)
Research institute
Hospital Universitario San Juan de Alicante
San Juan de Alicante, EspañaPublications in collaboration with researchers from Hospital Universitario San Juan de Alicante (9)
2023
-
Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients
Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215
2022
-
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study
Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864
-
Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study
The Lancet Regional Health - Europe, Vol. 18
2021
-
Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)
Critical Care
-
The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients
Critical Care, Vol. 25, Núm. 1
2016
-
Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
Critical Care, Vol. 20, Núm. 1
2011
-
Impact of obesity in patients infected with 2009 influenza A(H1N1)
Chest, Vol. 139, Núm. 2, pp. 382-386
2005
-
Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma
Cancer Chemotherapy and Pharmacology, Vol. 55, Núm. 2, pp. 197-202
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81